Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Operating Leases (2019 - 2025)

Fortress Biotech has reported Operating Leases over the past 7 years, most recently at $12.7 million for Q4 2025.

  • Quarterly results put Operating Leases at $12.7 million for Q4 2025, down 14.09% from a year ago — trailing twelve months through Dec 2025 was $12.7 million (down 14.09% YoY), and the annual figure for FY2025 was $12.7 million, down 14.09%.
  • Operating Leases for Q4 2025 was $12.7 million at Fortress Biotech, down from $12.8 million in the prior quarter.
  • Over the last five years, Operating Leases for FBIO hit a ceiling of $23.7 million in Q3 2022 and a floor of $12.7 million in Q4 2025.
  • Median Operating Leases over the past 5 years was $19.2 million (2023), compared with a mean of $18.5 million.
  • Biggest five-year swings in Operating Leases: grew 15.09% in 2023 and later dropped 25.16% in 2024.
  • Fortress Biotech's Operating Leases stood at $21.0 million in 2021, then grew by 2.79% to $21.6 million in 2022, then fell by 15.25% to $18.3 million in 2023, then dropped by 19.32% to $14.8 million in 2024, then dropped by 14.09% to $12.7 million in 2025.
  • The last three reported values for Operating Leases were $12.7 million (Q4 2025), $12.8 million (Q3 2025), and $13.3 million (Q2 2025) per Business Quant data.